Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma
the ONA take:
Single-agent aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed superior efficacy over doxorubicin and manageable adverse effects in patients with advanced soft-tissue sarcoma, a new study published online ahead of print in JAMA Oncology has shown.
For the international, multicenter, open-label, phase 2b study, researchers enrolled 126 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma. Participants were randomly assigned 2:1 to receive aldoxorubicin 350 mg/m2 or doxorubicin 75 mg/m2 administered intravenously once every 3 weeks for up to six cycles.
Results showed that median progression-free survival was significantly improved with aldoxorubicin compared with doxorubicin. In addition, 6-month progression-free survival rates and tumor response rates were significantly improved with aldoxorubicin.
In regard to safety, no acute cardiotoxic effects were observed with either treatment, but left ventricular ejection fraction less than 50% occurred in 3 of 40 patients who received doxorubicin. Grade 3 or 4 neutropenia occurred more frequently in the aldoxorubicin group.
The findings suggest that further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|